A $55,000 drug that doesn’t cure Alzheimer’s

Adam Feuerstein, a senior writer at Stat specializing in pharmaceuticals, delves into the FDA's controversial approval of Aduhelm, a $55,000 drug for Alzheimer's. He highlights the mixed responses from the scientific community regarding its effectiveness. The discussion also covers the ethical dilemmas tied to the drug's high cost and the implications for patients seeking hope in their treatment. Feuerstein raises critical questions about the relationship between the FDA and pharmaceutical companies, emphasizing the need for reform in drug approval processes.